CTLA4 and hepatocellular carcinoma: A HIMALAYA phase III trial (NCT03298451) is in progress to compare durvalumab (anti-PD-L1) with or without tremelimumab (anti-CTLA4) to sorafenib in first-line treatment of advanced HCC.